Currently, there are 168.51M common shares owned by the public and among those 117.21M shares have been available to trade.
The company’s stock has a 5-day price change of 82.10% and -2.09% over the past three months. XFOR shares are trading -19.69% year to date (YTD), with the 12-month market performance down to -23.50% lower. It has a 12-month low price of $0.26 and touched a high of $1.60 over the same period. XFOR has an average intraday trading volume of 2.54 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 67.29%, 37.86%, and -16.85% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of X4 Pharmaceuticals Inc (NASDAQ: XFOR) shares accounts for 35.58% of the company’s 168.51M shares outstanding.
It has a market capitalization of $114.84M and a beta (3y monthly) value of 0.32. The earnings-per-share (ttm) stands at -$0.09. Price movements for the stock have been influenced by the stock’s volatility, which stands at 19.87% over the week and 19.27% over the month.
Earnings per share for the fiscal year are expected to increase by 77.49%, and -282.93% over the next financial year.
Looking at the support for the XFOR, a number of firms have released research notes about the stock. B. Riley Securities stated their Neutral rating for the stock in a research note on December 12, 2023, with the firm’s price target at $3-$1. B. Riley Securities coverage for the X4 Pharmaceuticals Inc (XFOR) stock in a research note released on August 30, 2023 offered a Buy rating with a price target of $3. Cantor Fitzgerald was of a view on December 22, 2022 that the stock is Overweight, while Piper Sandler gave the stock Overweight rating on December 12, 2022, issuing a price target of $3. Oppenheimer on their part issued Outperform rating on December 23, 2019.
